Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


27. November 2020 | 10:24 CET

Varta, Royal Helium, NEL ASA: After the hype is before the hype

  • Investments
Photo credits: pixabay.com

The world is facing a whole series of revolutions. Digitalization is changing business models and the way we work and communicate. New energy sources are revolutionizing mobility. Between April and October, Varta's stock posted an impressive performance and generated a return of more than 150%. Recently, however, the share price has come down a little again. Reason enough to put the Company through its paces a little. Varta manufactures micro-batteries, such as those used in hearing aids or other household appliances. By the end of next year, Varta intends to expand its capacities in this area. The Company is also taking a step forward in terms of quality and plans to increase energy density further, and this is how the Company intends to stand out from the cheap competition.

time to read: 3 minutes by Nico Popp


 

Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author


Varta: Is history repeating itself?

In recent months, the share has been celebrated by investors, particularly for its fantasy about entering the field of electromobility. Thanks to public funding of EUR 300 million, Varta could gain access to a lucrative market. Coupled with the positive forecasts in the core business with batteries for hearing aids or headphones, this price fantasy has boosted the share.

However, the management could no longer convince analysts and the first observers expressed doubts about the equity story. The competition from Asia should also be mentioned in this context: It would not be the first time that German companies in a technology of the future are ultimately at a disadvantage compared to China, despite generous subsidies - the situation was similar years ago with photovoltaic stocks. The Varta share is, rightly, currently undergoing a consolidation. The music is out for now.

Royal Helium: Revaluation still in December?

The share of Royal Helium went into reverse in the past months. The Canadian second-tier stock is looking for the noble gas helium in the south of the Canadian province of Saskatchewan. The gas has unique properties and can be used in many areas: the largest area of application is in medical technology, where it is found in MRI equipment. The noble gas can also be used in the manufacture of computer chips and in the quality testing of batteries. Helium can thus do much more than making balloons rise. The analysts at Cormark Securities also see it that way and expect a shortage of helium in the coming years.

Royal Helium wants to take advantage of this and further advance its Canadian helium project. With 400,000 hectares of land and surrounded by crucial infrastructure, the property is considered promising. Royal Helium is currently conducting a technical investigation to evaluate the economics of a gas processing plant. The Company points out that the property may also have the potential to market by-products in the form of other gases. The Company plans to present the first results of the study in December. Royal Helium's shares may have attractive prospects due to the many uses of helium in the medical, semiconductor and battery sectors.

NEL ASA: Hydrogen hope at a crossroads

NEL's share certificates are also full of promise. The Norwegian hydrogen specialist takes care of the production of hydrogen, its storage and distribution. Thus, NEL covers all aspects of hydrogen. If you imagine a future full of hydrogen cars, you can hardly avoid solutions from the Norwegians. Hydrogen as an energy carrier is regarded as a clean alternative to lithium-ion batteries, as these are dependent on numerous critical metals, the promotion of which causes environmental damage.

Despite the rosy outlook and the catchy investment story, the NEL share has recently hit its head several times in the range of just over two euros. This zone of resistance has proven to be stubborn. According to the technical chart, the stock is now in a decision zone: If a sustained breakout above this resistance zone is achieved, further price momentum may emerge, and if the breakout is not successful, price losses are possible. Since NEL is already ambitiously valued, a correction cannot be ruled out.

The most significant opportunities are lurking among latecomers

Varta is a latecomer into the field of e-mobility but has already made significant gains. NEL, on the other hand, is a pioneer and well-positioned around hydrogen. The current hydrogen hype could lead to the market allowing even higher valuations. Nevertheless, investors should be aware of the high fall. Even if intact trends offer a good investment environment, it is also worth taking a look at the second tier. Helium-related stocks are also benefiting from a whole range of megatrends and are currently in low demand, allowing speculative-oriented investors to enter the market at favourable prices.


Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

20. April 2021 | 09:45 CET | by Stefan Feulner

Varta, Sierra Growth, CureVac - Clear signals!

  • Investments

Sometimes, for various reasons, it takes longer before the positive developments of a Company are absorbed by the market and thus provide for price gains. It is currently similar to the precious metal gold, which is still in the consolidation phase. The facts such as national debt, inflation fears and the ultra-loose monetary policy of the central banks speak another clear language.

Read

20. April 2021 | 07:10 CET | by Carsten Mainitz

BioNTech, SunMirror, Steinhoff - Great News!

  • Investments

Shortly before the finish line, the going gets tough again. Many athletes and those who have to really "bite" in the last few meters before a deadline are probably familiar with this feeling. Everyday life in the Corona pandemic is also becoming more exhausting. Now, with BioNTech's announcement that it will double weekly vaccine dose deliveries to around 5.1 million units from the end of May, there may be a breakthrough in achieving herd immunity in Germany in the next few months. It is not only good news for the Company's shareholders but everyone. Below we present two other companies whose shareholders should be very pleased. Let us surprise you!

Read

15. April 2021 | 07:15 CET | by Stefan Feulner

Alibaba, The Place Holdings, CureVac - Great opportunities lie here!

  • Investments

The German vaccination disaster is going into the next round. After the AstraZeneca vaccine's back and forth and the question of whether only younger people, older people or no one should be vaccinated with the vaccine, the American vaccine manufacturer Johnson & Johnson is now experiencing delivery stoppages. The return to "normality" once again seems to be a long way off. Another question to ask yourself. What will future life in the new normal look like in the hard-pressed inner cities?

Read